Skip to Content

'
Paul G. Corn, MD, PhD

Present Title & Affiliation

Primary Appointment

Assistant Professor of Medicine, Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX

Office Address

The University of Texas MD Anderson Cancer Center
1155 Pressler Street
Unit Number: 1374
Houston, TX 77030
Room Number: CPB7.3450

Education & Training

Degree-Granting Education

1993 Georgetown University, Washington, DC, MD, Medicine
1993 Georgetown University, Washington, DC, PHD, Microbiology
1985 Columbia University, New York, NY, BA, Sociology

Postgraduate Training

7/1996-6/2000 Fellowship Medical Oncology, Johns Hopkins Oncology, Baltimore, MD
7/1994-6/1996 Resident in Medicine, University of Chicago Hospital, Chicago, IL
7/1993-6/1994 Intern in Medicine, University of Chicago Hospital, Chicago, IL

Board Certifications

2010 American Board of Internal Medicine-Medical Oncology

Experience/Service

Academic Appointments

Instructor, Department of Medicine, University of Pennsylvania School of Medicine, Philadelphia, PA, 7/2000-9/2004

Administrative Appointments/Responsibilities

Medical Oncology Attending Physician, Hospital of the University of Pennsylvania, Philadelphia, PA, 1/2002-9/2004
Medical Oncology Attending Physician, Veterans Administration Hospital, Philadelphia, PA, 1/2002-1/2004

Honors and Awards

1994 Housestaff Recognition Award, University of Chicago, Department of Medicine
1993 Alpha Omega Alpha
1993 Mario Mollari Award, Award for Outstanding Performance in the Department of Microbiology, Georgetown University Medical School
1993 The Gregory M. Chirikjian Award, Georgetown University Medical School
1991 Georgetown University, 2nd Place, Medical Research Day, Pre-doctoral Division
1990 Bioethics Essay Award, Washington Academy of Medicine
1989 Student Research Award, American Society of Microbiology

Selected Publications

Peer-Reviewed Original Research Articles

1. Song G, Valdez BC, Li Y, Dominguez JR, Corn P, Champlin RE, Andersson BS. The histone deacetylase inhibitor SAHA sensitizes AML cells to a combination of nucleoside analogs and the DNA-alkylating agent busulfan. Leuk Lymphoma. e-Pub 10/21/2013. PMID: 24144307.
2. Matrana MR, Duran C, Shetty A, Xiao L, Atkinson BJ, Corn P, Pagliaro LC, Millikan RE, Charnsangave C, Jonasch E, Tannir NM. Outcomes of patients with metastatic clear-cell renal cell carcinoma treated with pazopanib after disease progression with other targeted therapies. Eur J Cancer 49(15):3169-75, 10/2013. e-Pub 6/2013. PMID: 23810246.
3. Atkinson BJ, Kalra S, Wang X, Bathala T, Corn P, Tannir NM, Jonasch E. Clinical Outcomes in Metastatic Renal Cell Carcinoma Patients Treated with Alternative Sunitinib Schedules. J Urol. e-Pub 9/6/2013. PMID: 24018239.
4. Atkinson BJ, Cauley DH, Ng C, Millikan RE, Xiao L, Corn P, Jonasch E, Tannir NM. mTOR inhibitor associated noninfectious pneumonitis in patients with renal cell cancer: management, predictors, and outcomes. BJU Int. e-Pub 8/23/2013. PMID: 24053120.
5. Aparicio AM, Harzstark AL, Corn PG, Wen S, Araujo JC, Tu SM, Pagliaro LC, Kim J, Millikan RE, Ryan C, Tannir NM, Zurita AJ, Mathew P, Arap W, Troncoso P, Thall PF, Logothetis CJ. Platinum-Based Chemotherapy for Variant Castrate-Resistant Prostate Cancer. Clin Cancer Res. e-Pub 6/18/2013. PMID: 23649003.
6. Karantanos T, Corn PG, Thompson TC. Prostate cancer progression after androgen deprivation therapy: mechanisms of castrate resistance and novel therapeutic approaches. Oncogene. e-Pub 6/10/2013. PMID: 23752182.
7. Abouharb S, Corn PG. Optimal Therapy Sequencing in Metastatic Castration-Resistant Prostate Cancer. Curr Oncol Rep. e-Pub 4/9/2013. PMID: 23568599.
8. Corn PG, Song DY, Heath E, Maier J, Meyn R, Kuban D, Depetrillo TA, Mathew P. Sunitinib Plus Androgen Deprivation and Radiation Therapy for Patients With Localized High-Risk Prostate Cancer: Results From a Multi-institutional Phase 1 Study. Int J Radiat Oncol Biol Phys. e-Pub 3/28/2013. PMID: 23541810.
9. Smith DC, Smith MR, Sweeney C, Elfiky AA, Logothetis C, Corn PG, Vogelzang NJ, Small EJ, Harzstark AL, Gordon MS, Vaishampayan UN, Haas NB, Spira AI, Lara PN, Lin CC, Srinivas S, Sella A, Schöffski P, Scheffold C, Weitzman AL, Hussain M. Cabozantinib in Patients With Advanced Prostate Cancer: Results of a Phase II Randomized Discontinuation Trial. J Clin Oncol 31(4):412-9, 2013. e-Pub 11/2012. PMID: 23169517.
10. McGuire SE, Lee AK, Cerne JZ, Munsell MF, Levy LB, Kudchadker RJ, Choi SL, Nguyen QN, Hoffman KE, Pugh TJ, Frank SJ, Corn PG, Logothetis CJ, Kuban DA. PSA Response to Neoadjuvant Androgen Deprivation Therapy Is a Strong Independent Predictor of Survival in High-Risk Prostate Cancer in the Dose-Escalated Radiation Therapy Era. Int J Radiat Oncol Biol Phys. e-Pub 10/23/2012. PMID: 23102837.
11. Som A, Tu SM, Liu J, Wang X, Qiao W, Logothetis C, Corn PG. Response in bone turnover markers during therapy predicts overall survival in patients with metastatic prostate cancer: analysis of three clinical trials. Br J Cancer 107(9):1547-53, 10/23/2012. e-Pub 10/2/2012. PMCID: PMC3493771.
12. Corn PG. The tumor microenvironment in prostate cancer: elucidating molecular pathways for therapy development. Cancer Management and Research 4:183-193, 7/2012. e-Pub 7/2012.
13. Gallick GE, Corn PG, Zurita AJ, Lin SH. Small-molecule protein tyrosine kinase inhibitors for the treatment of metastatic prostate cancer. Future Med Chem 4(1):107-19, 1/2012. PMID: 22168167.
14. Varkaris A, Corn PG, Gaur S, Dayyani F, Logothetis CJ, Gallick GE. The role of HGF/c-Met signaling in prostate cancer progression and c-Met inhibitors in clinical trials. Expert Opin Investig Drugs. e-Pub 10/28/2011. PMID: 22035268.
15. Dayyani F, Gallick GE, Logothetis CJ, Corn PG. Novel Therapies for Metastatic Castrate-Resistant Prostate Cancer. J Natl Cancer Inst. e-Pub 9/13/2011. PMID: 21917607.
16. Corn PG. Using methylation analysis to assess tumor heterogeneity in familial breast cancer. Cancer Biol Ther 11(12). e-Pub 6/15/2011. PMID: 21577053.
17. Tsao CC, Corn PG. MDM-2 antagonists induce p53-dependent cell cycle arrest but not cell death in renal cancer cell lines. Cancer Biol Ther 10(12), http://www.landesbioscience.com/journals/5/article/13612/. e-Pub 12/2010. PMID: 20953142.
18. Richey SL, Culp SH, Jonasch E, Corn PG, Pagliaro LC, Tamboli P, Patel KK, Matin SF, Wood CG, Tannir NM. Outcome of patients with metastatic renal cell carcinoma treated with targeted therapy without cytoreductive nephrectomy. Ann Oncol. e-Pub 11/29/2010. PMID: 21115604.
19. Choueiri TK, Lim ZD, Hirsch MS, Tamboli P, Jonasch E, McDermott DF, Cin PD, Corn P, Vaishampayan U, Heng DY, Tannir NM. Vascular endothelial growth factor-targeted therapy for the treatment of adult metastatic Xp11.2 translocation renal cell carcinoma. Cancer. e-Pub 7/21/2010. PMID: 20665500.
20. Corn PG, Thompson TC. Identification of a novel prostate cancer biomarker, caveolin-1: Implications and potential clinical benefit. Dovepress: Cancer Management and Research 2010:2:11-122, http://www.dovepress.com/identification-of-a-novel-prostate-cancer-biomarker-caveolin-1-implica-peer-reviewed-article-CMR, 5/2010. e-Pub 5/2010.
21. Valdez BC, Li Y, Murray D, Corn P, Champlin RE, Andersson BS. 5-Aza-2'-deoxycytidine sensitizes busulfan-resistant myeloid leukemia cells by regulating expression of genes involved in cell cycle checkpoint and apoptosis. Leuk Res 34(3):364-72, 3/2010. e-Pub 9/3/2009. PMCID: PMC2823987.
22. Jonasch E, Corn P, Pagliaro LC, Warneke CL, Johnson MM, Tamboli P, Ng C, Aparicio A, Ashe RG, Wright JJ, Tannir NM. Upfront randomized phase II trial of sorafenib versus sorafenib and low-dose interferon alpha in patients with advanced renal cell carcinoma. Cancer 116(1):57-65, 1/1/2010. PMID: 19862815.
23. Corn PG. Methylation marks the path for biomarker development in breast cancer research. Cancer Biol Ther 8(23):2260-62, 12/2009. e-Pub 12/25/2009. PMID: 19901521.
24. Araujo JC, Poblenz A, Corn P, Parikh NU, Starbuck MW, Thompson JT, Lee F, Logothetis CJ, Darnay BG. Dasatinib inhibits both osteoclast activation and prostate cancer PC-3 cell-induced osteoclast formation. Cancer Biol Ther 8(22):2151-7, 11/2009. e-Pub 11/8/2009. PMID: 19855158.
25. Jonasch E, Wood CG, Matin SF, Tu SM, Pagliaro LC, Corn PG, Aparicio A, Tamboli P, Millikan RE, Wang X, Araujo JC, Arap W, Tannir N. Phase II presurgical feasibility study of bevacizumab in untreated patients with metastatic renal cell carcinoma. J Clin Oncol 27(25):4076-81, 9/1/2009. e-Pub 7/27/2009. PMID: 19636008.
26. Pataer A, Swisher SG, Roth JA, Logothetis CJ, Corn PG. Inhibition of RNA-dependent protein kinase (PKR) leads to cancer cell death and increases chemosensitivity. Cancer Biol Ther 8(3):245-52, 2/2009. e-Pub 2/2009. PMCID: PMC2854203.
27. Tsao CC, Teh BT, Jonasch E, Shreiber-Agus N, Efstathiou E, Hoang A, Czerniak B, Logothetis C, Corn PG. Inhibition of Mxi1 suppresses HIF-2alpha-dependent renal cancer tumorigenesis. Cancer Biol Ther 7(10):1619-27, 10/2008. e-Pub 10/2008. PMID: 19018165.
28. Kojima K, Shimanuki M, Shikami M, Samudio IJ, Ruvulo V, Corn P, Hanoaka N, Konopleva M, Andreef M, Nakakuma H. The dual P13 kinase/mTOR inhibotor P1-103 prevents p53 induction by Mdm2 inhibition but enhances p53-mediated mitochondrial apoptosis in p53 wild-type AML. Leukemia 22(9):1728-36, 9/2008. PMID: 18548093.
29. Gardner LB, Corn PG. Hypoxic regulation of mRNA expression. Cell Cycle 7(13):1916-24, 7/1/2008. e-Pub 4/24/2008. PMID: 18604161.
30. Corn PG,. Genome-wide profilling of methylated promoters in pancreatic adenocarcinoma:defining the pancreatic cancer epigenome. Cancer Biol Ther 7(7):1157-9, 7/2008. e-Pub 7/2008. PMID: 18698160.
31. Corn PG. Hypoxic regulation of miR-210: Shrinking targets expand HIF-1's influence. Cancer Biol Ther 7(2):265-7, 2/2008. e-Pub 2/18/2008. PMID: 18347426.
32. Corn PG, El-Deiry WS. Microarray analysis of p53-dependent gene expression in response to hypoxia and DNA damage. Cancer Biol Ther 6(12):1858-66, 12/2007. e-Pub 11/20/2007. PMID: 18087215.
33. Corn PG. Role of the Ubiquitin-proteasome system in Renal Cell Carcinoma. BMC Biochem 8 Suppl(1:S4):S4, 2007. PMCID: PMC2106368.
34. Corn PG. Reactivation of p53 function with a demethylating agent. Cancer Biol Ther 5(9):1161-2, 9/2006. PMID: 17012838.
35. Corn PG, Ricci MS, Scata KA, Arsham AM, Simon MC, Dicker DT, El-Deiry WS. Mx1 is induced by hypoxia in a HIF-1 dependent manner and protects cells from c-Myc-induced apoptosis. Cancer Biol Ther 4(11):1285-94, 11/2005. e-Pub 11/7/2005. PMID: 16319523.
36. Rikhof B, Corn PG, El-Deiry WS. Caspase 10 levels are increased following DNA damage in a p53-dependent manner. Cancer Biol Ther 2(6):707-12, Nov-Dec, 11/2003. PMID: 14688482.
37. Corn PG, McDonald ER, Herman JG, El-Deiry WS. Tat-binding protein-1, a component of the 26S proteasome, contributes to the E3 ubiquitin ligase function of the von Hippel-Lindau protein. Nat Genet 3(3):229-37, 11/2003. e-Pub 10/12/2003. PMID: 14556007.
38. Corn PG, Summers MK, Fogt F, Virmani AK, Gazdar AF, Halazonetis TD, El-Deiry WS. Frequent hypermethylation of the 5' CpG island of the mitotic stress checkpoint gene Chfr in colorectal and non-small cell lung cancer. Carcinogenesis 24(1):47-51, 1/2003. PMID: 12538348.
39. Corn PG, El-Deiry WS. Derangement of growth and differentiation control in oncogenesis. Bioessays 24(1):83-90, 1/2002. PMID: 11782953.
40. Corn PG, Heath EI, Heitmiller R, Fogt F, Forastiere AA, Herman JG, Wu TT. Frequent hypermethylation of the 5' CpG island of E-cadherin in esophageal adenocarcinoma. Clin Cancer Res 7(9):2765-9, 9/2001. PMID: 11555590.
41. Nicholson SA, Okby NT, Khan MA, Welsh JA, McMenamin MG, Travis WD, Jett JR, Tazelaar HD, Trastek V, Pairolero PC, Corn PG, Herman JG, Liotta LA, Caporaso NE, Harris CC. Alterations of p14ARF, p53, and p73 genes involved in the E2F-1-mediated apoptotic pathways in non-small cell lung carcinoma. Cancer Res 61(4):5636-43, 7/15/2001. PMID: 11454718.
42. Esteller M, Cordon-Cardo C, Corn PG, Meltzer SJ, Pohar KS, Watkins DN, Capella G, Peinado MA, Matias-Guiu X, Prat J, Baylin SB, Herman JG. p14ARF silencing by promoter hypermethylation mediates abnormal intracellular localization of MDM2. Cancer Res 61(7):2816-21, 4/1/2001. PMID: 11306450.
43. Corn PG, Esteller M, Baylin SB, Herman JG. A gene hypermethylation profile of human cancer. Cancer Res 61(8):3225-9, 4/2001. PMID: 11309270.
44. Corn PG, Smith BD, Ruckdeschel ES, Douglas D, Baylin SB, Herman JG. E-cadherin expression is silenced by 5'CpG island methylation in acute leukemia. Clin Cancer Res 6(11):4243-8, 11/2000. PMID: 11106238.
45. Esteller M, Avizienyte E, Corn PG, Lothe RA, Baylin SB, Aaltonen LA, Herman JG. Epigenetic inactivation of LKB1 in primary tumors associated with the Peutz-Jeghers syndrome. Oncogene 19(1):164-8, 1/6/2000. PMID: 10644993.
46. Corn PG, Kuerbitz SJ, van Noesel MM, Esteller M, Compitello N, Baylin SB, Herman JG. Transcriptional silencing of the p73 gene in acute lymphoblastic leukemia and Burkitt's lymphoma is associated with 5'CpG island methylation. Cancer Res 59(14):3352-6, 7/15/1999. PMID: 10416592.
47. Bachman KE, Herman JG, Corn PG, Merlo A, Costello JF, Cavenee WK, Baylin SB, Graff JR. Methylation-associated silencing of the tissue inhibitor of metalloproteinase-3 gene suggest a suppressor role in kidney, brain, and other human cancers. Cancer Res 59(4):798-802, 2/15/1999. PMID: 10029065.
48. Esteller M, Corn PG, Urena JM, Gabrielson E, Baylin SB, Herman JG. Inactivation of glutathione S-transferase P1 gene by promoter hypermethylation in human neoplasia. Cancer Res 58(20):4515-8, 10/15/1998. PMID: 9788592.
49. Corn PG, Anders J, Takala AK, Käyhty H, Hoiseth SK. Genes involved in haemophilus influenzae type b capsule expression are frequently amplified. J Infect Dis 167(2):356-64, 2/1993. PMID: 8421169.
50. Hoiseth SK, Corn PG, Anders J. Amplification status of capsule genes in Haemophilus influenzae type b clinical isolates. J Infect Dis 165 Suppl 1:S114, 6/1992. PMID: 1588141.
51. Corn PG, Mulroney SE, Haramati A. Restoration of a phosphaturic response to parathyroid hormone in the immature rat. Pediatr Res 26(1):54-7, 7/1989. PMID: 2771508.

Abstracts

1. Atkinson BJ, Kalra S, Wang X, Bathala T, Perpich J, Corn PG, Tannir NM, Jonasch E. Outcomes associated with sunitinib alternative schedule compared to traditional schedule: a single-center experience. J Clin Oncol (#e15611), 12/2013.
2. Jonasch E, Corn PG, Pagliaro LC, Lara P, Wang X, Do KA, Garza R, Bird S, Drabick JJ, Marcott V, Quinn D, Doyle A, Tannir NM. Randomized phase II CTEP study of MK2206 versus everolimus in VEGF inhibitor refractory renal cell carcinoma patients. J Clin Oncol (#4517), 12/2013.
3. Scher HI, Smith MR, Sweeney C, Corn PG, Logothetis C, Vogelzang NJ, Smith DC, Hussain M, George DJ, De Bono JS, Higano CS, Small EJ, Goldin J, Brown MS, Aftab DT, Noursalehi M, Weitzman A, Basch EM. An exploratory analysis of bone scan lesion area (BSLA), circulating tumor cell (CTC) change, pain reduction, and overall survival (OS) in patients (pts) with castration-resistant prostate cancer (CRPC) treated with cabozantinib (cabo): Updated results of a phase II nonrandomized expansion (NRE) cohort. J Clin Oncol (#5026), 2013.
4. Corn PG, Varkaris A, Tapia EM, Araujo JC, Aparicio A, Tu SM, Zurita AJ, Efstathiou E, Qiao W, Wen S, Gallick GE, Logothetis C. Modulation of soluble c-Met, bone turnover markers, angiogenic factors, and c-Met in men with mCRPC treated with cabozantinib. J Clin Oncol (#58), 2013.
5. Cauley DH, Atkinson BJ, Chaan NS, Millikan RE, Xiao L, Corn PG, Jonasch E, Tannir NM. mTOR inhibitor-associated noninfectious pneumonitis in patients with metastatic renal cell cancer: A single-center experience. J Clin Oncol (#e15612), 2013.
6. Matrana MR, Duran C, Shetty A, Xiao L, Atkinson BJ, Corn PG, Charnsangavej C, Jonasch E, Tannir NM. Outcomes of patients (pts) with metastatic renal cell carcinoma (mRCC) treated with pazopanib after progression on other targeted therapies (TT): Updated results. J Clin Oncol (#367), 2013.
7. Hussain M, Corn PG, Michaelson D, Hammers HJ, Alumkal JJ, Ryan CJ, Bruce JY, Moran S, MacLean D, Lee S, Lin MH, Zhu Y, Shi H, Mortimer P, George DJ. Safety, efficacy, and health-related quality of life (HRQoL) of the investigational single agent orteronel (ortl) in nonmetastatic castration-resistant prostate cancer (nmCRPC). J Clin Oncol (#5076), 2013.
8. Dayyani F, Nogueras-Gonzalez GM, Slack R, Millikan RE, Zurita AJ, Araujo JC, Gallick GE, Logothetis C, Corn PG. Serum insulin to predict time to castration-resistant progression and overall survival in metastatic androgen-dependent prostate cancer (mADPCa). J Clin Oncol (#e16038), 2013.
9. Jonasch E, Wood CG, Corn PG, Sharma P, Pagliaro LC, Aparicio A, Do KA, Wang X, Marcott VD, Matin SF, Tannir NM. Using presurgical sunitinib to select patients with newly diagnosed metastatic clear cell renal cell carcinoma for cytoreductive nephrectomy: A phase II study. J Clin Oncol (#371), 2013.
10. Smith MR, Sweeney C, Rathkopf DE, Scher HI, Logothetis C, George DJ, Higano CS, Yu EY, Harzstark AL, Small EJ, Sartor AO, Gordon MS, Vogelzang NJ, Smith DC, Hussain M, De Bono JS, Haas NB, Scheffold C, Lee Y, Corn PG. Cabozantinib (XL184) in chemotherapy-pretreated metastatic castration resistant prostate cancer (mCRPC): Results from a phase II nonrandomized expansion cohort (NRE). J Clin Oncol (#4513), 2012.
11. Cauley DH, Atkinson BJ, Ng CS, Wang X, Xiao L, Corn PG, Jonasch E, Tannir NM. Everolimus (E) and temsirolimus (T) associated penumonitis (P) in metastatic renal cell cancer patients (mRCC): A single-center experience. J Clin Oncol (#401), 2012.
12. Siefker-Radtke AO, Kamat AM, Corn PG, Matin SF, Grossman HB, Millikan RE, Dinney CPN. Neoadjuvant chemotherapy with DD-MVAC and bevacizumab in high-risk urothelial cancer: Results from a phase II trial at the University of Texas M. D. Anderson Cancer Center. J Clin Oncol (#4523), 2012.
13. Matrana MR, Shetty AV, Atkinson BJ, Xiao L, Corn PG, Millikan RE, Jonasch E, Tannir NM. Outcomes of patients (pts) with metastatic renal cell carcinoma (mRCC) treated with pazopanib after progression on other targeted therapies (TT): A single-institution experience. J Clin Oncol (#4516), 2012.
14. George DJ, Corn PG, Michaelson MD, Hammers HJ, Alumkal JJ, Ryan CJ, Bruce JY, Moran S, Lee SY, Mortimer P, Hussain M. Safety and activity of the investigational agent orteronel (ortl) without prednisone in men with nonmetastatic castration-resistant prostate cancer (nmCRPC) and rising prostate-specific antigen (PSA): Updated results of a phase II study. J Clin Oncol (#4549), 2012.
15. Matrana MR, Shetty AV, Atkinson BJ, Xiao L, Corn PG, Millikan RE, Jonasch E, Tannir NM. Therapies and outcomes of non-renal cell carcinoma (non-RCC) neoplasms of the kidney: A single-institution experieince. J Clin Oncol (#4615), 2012.
16. Bilen MA, Liu D, Mathew P, Pagliaro LC, Logothetis C, Araujo JC, Aparicio A, Corn PG, Hajdenberg J, Dakhil SR, Tu S. A randomized phase II study of bone-targeted therapy in advanced androgen-dependent prostate cancer. J Clin Oncol (#4649), 2011.
17. Hussain M, Smith MR, Sweeney C, Corn PG, Elfiky A, Gordon MS, Haas NB, Harzstark AL, Kurzrock R, Lara P, Lin C, Sella A, Small EJ, Spira AI, Vaishampayan UN, Vogelzang NJ, Scheffold C, Ballinger MD, Schimmoller F, Smith DC. Cabozantinib (XL184) in metastatic castration-resistant prostate cancer (mCRPC): Results from a phase II randomized discontinuation trial. J Clin Oncol (#4516), 2011.
18. Aparicio A, Harzstark L, Lin E, Corn P, Araujo J, Tu S, Pagliaro L, Millikan R, Arap W, Kim J, Ryan C, Zurita A, Tannir N, Lin A, Small J, Mathew P, Jones D, Troncoso P, Thall P, Logothetis C. Characterization of the anaplastic prostate carcinomas: A prospective two-stage phase II trial of frontline carboplatin and docetaxel (CD) and salvage etoposide and cisplatin (EP). J Clin Oncol (#4666), 2011.
19. Cauley DH, Atkinson BJ, Corn PG, Jonasch E, Tannir NM. Everolimus-associated pneumonitis (EAP) in metastatic renal cell cancer patients (mRCC): A single-center experience. J Clin Oncol (#332), 2011.
20. Richey SL, Culp SH, Jonasch E, Corn PG, Pagliaro LC, Matin SF, Wood CG, Tannir NM. Long-term survival of patients with metastatic renal cell carcinoma (mRCC) treated with targeted therapy (TT) without cytoreductive nephrectomy (CN). J Clin Oncol (#346), 2011.
21. Matrana M, Atkinson B, Corn P, Jonasch E, Tannir MN. Metastatic RCC treated with pazopanib after progression on other targeted agents a single-institution experience. J Clin Oncol (#351), 2011.
22. Jonasch E, Wood CG, Pagliaro LC, Corn PG, Aparicio A, Marcott VD, Matin SF, Tannir NM. Presurgical sunitinib in patients with newly diagnosed metastatic renal cell carcinoma (mRCC): Interim toxicity and feasibility analysis. J Clin Oncol (#e15083), 2010.
23. Dubauskas Lim Z, Choueiri TK, Hirsch MS, Jonasch E, Vaishampayan UN, Tamboli P, Corn PG, Heng DY, Tannir NM. Vascular endothelial growth factor (VEGF)-targeted therapy for the treatment of adult metastatic Xp11 translocation renal cell carcinoma. J Clin Oncol (#4606), 2010.
24. Tsao CC, Corn PG. Nutlin-3a induces growth arrest in kidney cancer cell lines in a p53-dependent manner. AACR - 100th Annual Meeting, 2009.
25. Richey SL, Culp SH, Wood CG, Corn PG, Jonasch E, Tannir NM. Outcome of patients with metastatic renal cell carcinoma treated with systemic therapy without cytoreductive nephrectomy. J Clin Oncol (#16035), 2009.
26. Jonasch E, Tsavachidou D, Wood CG, Matin SF, Corn PG, Tamboli P, Wang X, Tannir N. Phase II presurgical study of bevacizumab plus erlotinib in untreated patients with metastatic renal cell carcinoma. J Clin Oncol (#5004), 2009.
27. Tannir NM, Zurita AJ, Heymach JV, Tran HT, Pagliaro LC, Corn P, Aparicio AM, Ashe R, Wright JJ, Jonasch E. A randomized phase II trial of sorafenib versus sorafenib plus low-dose interferon-alfa:Clinical results and biomarker analysis. ASCO Proceedings 5093, 2008.
28. Jonasch E, Corn P, Ashe RG, Do K, Tannir NM. Randomized phase II study of sorafenib with or without low-dose IFN in patients with metastatic renal cell carcinoma. Journal of Clinical Oncology 5104, 2007. e-Pub 6/2007.
29. Tsavachidou D, Tannir NM, Wood CG, Corn P, Do K, Tamboli P, Smith LA, Matin S, Jonasch E. Von Hippel-Lindau gene mutation stuatus is associated with a dichotomous response in primary and metastatic tumors in patients receiving bevacizumab and erlotinib for metastatic renal cell carcinoma. Journal of Clinical Oncology 15522, 2007. e-Pub 6/2007.
30. Song Y-H, Navone NM, Corn P, Troncoso P, Alt E. The interaction between prostate cancer cells and tissue-resident stem cells influences tumor growth, metastasis and treatment strategies. V Foundation. Submitted.

Book Chapters

1. Kantarjian,Hago M. Koller,Charles A. ,. Wolff, Robert A, Corn, Paul G, Logothetis, Christopher. The Management of Prostate Cancer. In: The M D Anderson Manual of Medical Oncology, 2. McGraw-Hill, 2010.

Grant & Contract Support

Title: Building on FGFR inhibition to Develop Effective Combination Therapies
Funding Source: PCF-Creativity Award
Role: Co-Principal Investigator
Principal Investigator: Dr. Nora Navone
Duration: 3/15/2010 - 3/14/2012
 
Title: MD Anderson Cancer Center Prostate Cancer Research Program Clinical Consortium Award
Funding Source: Department of Defense (DOD)
Role: Co-Principal Investigator
Principal Investigator: Christopher Logothetis
Duration: 9/1/2009 - 9/30/2014
 
Title: Prostate Cancer Research
Funding Source: Robert Lawrence Fund
Role: Principal Investigator
Duration: 10/2008 - present
 
Title: Sunitinib, hormonal ablation and external beam radiation therapy for high-risk and locally advanced prostate cancer.
Funding Source: Pfizer Pharmaceuticals
Role: Principal Investigator
Duration: 8/2/2007 - 8/31/2010
 
Title: A randomized phase II study of two dose levels of ATN-224 in patients with biochemically relapsed, hormone-naive prostate cancer.
Funding Source: Attenuon
Role: Principal Investigator
Duration: 10/18/2006 - 10/18/2011
 
Title: Development of Novel Therapies in Prostate Cancer
Funding Source: Inveco International Inc.
Role: Principal Investigator
Duration: 2/1/2006 - 12/31/2007
 
Title: Tumor Hypoxia in Prostate Cancer Progression
Funding Source: Prostate Cancer Foundation (PCF)
Role: Principal Investigator
Duration: 11/1/2005 - 11/1/2008
 
Title: Tumor Hypoxia in Prostate Cancer Progression
Funding Source: NIH/NCI
Role: Principal Investigator
Duration: 4/22/2005 - 12/31/2007
 
Title: Regulation of the von Hippel-Lindau Protein
Funding Source: NIH/NCI
Role: Principal Investigator
Duration: 9/9/2003 - 8/31/2009

Last updated: 4/17/2014